University of Colorado Health Sciences Center

Quality of life (QoL) scores improved over 15 months in patients with 

 who treated breakthrough attacks with sebetralstat while on long-term prophylaxis (LTP), according to the recent KONFIDENT-S open-label extension analysis.

 Investigator Daniel F. Soteres, MD, MPH, a physician from Asthma & Allergy Associates, PC, discussed what those gains mean for patients already considered well-controlled.

“When you think about using a new medication, we want to know: Is it safe? Is it effective? And then our patients definitely want to know…what will it offer them in terms of improvement in their quality of life,” Soteres said.

Sebetralstat Shows QoL Gains on Top of HAE Prophylaxis in KONFIDENT-S

The analysis included 35 participants with type 1 HAE who experienced a total of 504 breakthrough attacks despite being on a long-term prophylaxis of either berotralstat (n = 16), lanadelumab (n = 13), or C1 inhibitor replacement (n = 6). With sebtralstat, the median time to the beginning of symptom relief was 1.3 hours for both berotralstat and lanadelumab and 1.8 hours for C1 inhibitor LTP.¹ Only 1.6% of the breakthrough attacks went untreated, and 22.3% of attacks required a second dose of sebtralstat within 12 hours.

The median time from attack recognition to sebetralstat administration was 6 minutes overall. This ranged from 1 minute in participants on C1 inhibitor LTP to 20 minutes in those on berotralstat. In this study, nearly 30% of attacks were treated while still mild.

Sebetralstat Improves Quality of Life in HAE

QoL scores were available for 34 participants. Among these patients, Angioedema Quality of Life Instrument scores improved by a squares mean of 10.3 points (−21.1 to 0.6) from baseline to month 15, exceeding the threshold considered clinically meaningful. The largest gains were in the fatigue/mood (-13.3), followed by gains in fears/shame (-11.2) and functioning (-9.6).¹ Treatment satisfaction was high, with 88.8% of sebetralstat-treated attacks rated satisfactory and 75.0% rated very or extremely satisfactory.¹

The Smaller C1 Inhibitor Subgroup in KONFIDENT-S

Effectiveness signals looked somewhat different among the 6 participants receiving C1 inhibitor (C1INH) LTP, whose median time to complete attack resolution was 16.6 hours versus 10.9 hours for berotralstat and 15.1 hours for lanadelumab.¹ Soteres cautioned against overinterpreting the small subgroup, noting patients on C1INH may be more accustomed to relief from injectable therapies, representing "a real paradigm shift" in understanding that a pill could offer comparable results. He added there could also be subtle differences in disease chemistry that respond more slowly, though efficacy still held for these patients.

Soteres said the findings reinforce existing guidance rather than change it: patients with HAE, including those stable on LTP, should keep 2 doses of on-demand therapy available at all times, a standard he has built into his own practice. He said sebetralstat's oral route remains a favorable on-demand option even for patients who continue to have it available alongside injectable choices.

Read part 1 of our interview with Soteres here: 

Sebetralstat Resolves Breakthrough HAE Attacks Despite Prior Prophylaxis.

Editor’s note: Reported disclosures for Soteres include KalVista Pharmaceuticals, BioCryst, CSL Behring, Intellia Therapeutics, Ionis Pharmaceuticals, Pharming, Pharvaris, and Takeda.

Kinaciyan T, Aygören-Pürsün E, Martinez-Saguer I, et al. Sebetralstat for breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis in KONFIDENT-S. 

. 2026;5(5):100750. Published 2026 Jun 12. 

Johnson V. Sebetralstat Shows Long Term Fast Relief of Breakthrough HAE Attacks. HCPLive. Published July 21, 2026. Accessed July 24, 2026. 

https://www.hcplive.com/view/sebetralstat-shows-long-term-fast-relief-breakthrough-hae-attacks

Soteres D. Sebetralstat Resolves Breakthrough HAE Attacks Despite Prior Prophylaxis. HCPLive. Published July 24, 2026. Accessed July 24, 2026. 

https://www.hcplive.com/view/sebetralstat-resolves-breakthrough-hae-attacks-prior-prophylaxis

Videos

Daniel Soteres, MD, discusses KONFIDENT-S data showing sebetralstat improved quality of life for HAE patients already stable on long-term prophylaxis.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Welcome to The HCPFive, your go-to roundup for the latest healthcare news and breakthroughs, curated specifically for busy healthcare professionals.

Each week, we highlight 5 key developments or headlines from healthcare that you need to know — whether it's a cutting-edge treatment, regulatory updates, or innovations shaping the future of medicine. This week's top stories include Agios’ discontinuation of tebapivat’s clinical development program for sickle cell disease, the US Food and Drug Administration (FDA) approval of olopatadine hydrochloride and mometasone furoate (Ryaltris) nasal spray, 665 mcg/25 mcg per spray, for the treatment of seasonal 

 symptoms in children aged 6 to 11 years, positive topline results for the global phase 3 SHASTA-3 and SHASTA-4 clinical studies of plozasiran in patients with severe 

, the FDA acceptance of BridgeBio’s New Drug Application (NDA) for encaleret for the treatment of 

autosomal dominant hypocalcemia type 1 (ADH1)

, and the FDA approval of MannKind Corporation’s furosemide injection (Furoscix ReadyFlow) for the treatment of edema (fluid overload) in adults with 

With The HCPFive, you'll get the essential takeaways to stay informed and ahead of the curve. Here's your quick dive into the top stories for the week of July 19, 2026 — let's jump in!

Agios Ends Tebapivat Development in Sickle Cell Disease After Phase 2

On July 21, 2026, Agios announced topline results from a phase 2 trial of tebapivat in patients aged ≥16 years with sickle cell disease showing improvements in hemoglobin and markers of hemolysis. However, the results did not demonstrate sufficient differentiation to support continued development of the pyruvate kinase (PK) activator, prompting the Company to discontinue the program.

"These phase 2 data further reinforce PK activation as a clinically validated mechanism in sickle cell disease, with tebapivat demonstrating hematologic activity consistent with this class of medicine," said Sarah Gheuens, MD, PhD, chief medical officer and head of research and development at Agios, in a statement. "However, the results did not establish the level of differentiation we believe is necessary to support continued development."

FDA Approves Ryaltris for Children Aged 6 to 11 With Seasonal Allergic Rhinitis

On July 21, 2026, the FDA expanded the approved use of olopatadine hydrochloride and mometasone furoate (Ryaltris) nasal spray, 665 mcg/25 mcg per spray, to include the treatment of seasonal allergic rhinitis symptoms in children aged 6 to 11 years. With the approval, the treatment is now indicated for adults and pediatric patients aged ≥ 6 years in the United States, broadening access to a younger population than the drug's original 2022 approval for patients aged ≥ 12 years.

Plozasiran Meets Primary Endpoint in SHASTA-3, SHASTA-4 sHTG Trials

On July 22, 2026, Arrowhead Pharmaceuticals announced topline results for the global phase 3 SHASTA-3 and SHASTA-4 clinical studies of plozasiran in patients with severe hypertriglyceridemia. Both trials successfully met the primary endpoint of triglyceride reduction versus placebo and met all prespecified secondary endpoints, including a statistically significant reduction in the rate of acute pancreatitis compared to placebo.

FDA Accepts NDA for Encaleret for Autosomal Dominant Hypocalcemia Type 1

Only July 22, 2026, the FDA accepted BridgeBio’s New Drug Application (NDA) for encaleret for the treatment of ADH1, assigning a Prescription Drug User Fee Act (PDUFA) date of May 8, 2027. If approved, encaleret will be the only therapy indicated specifically for patients with ADH1. The orally administered small molecule designed to selectively negatively modulate the calcium sensing receptor has previously received Fast Track Designation from the FDA and Orphan Drug Designation in the US, European Union, and Japan.

FDA Approves Furosemide Injection (Furoscix ReadyFlow) for Edema in HF, CKD

On July 24, 2026, the FDA approved MannKind Corporation’s furosemide injection (Furoscix ReadyFlow) for the treatment of edema (fluid overload) in adults with heart failure or chronic kidney disease, making it the first and only autoinjector delivering subcutaneous furosemide with IV-equivalent exposure (based on comparisons of AUC and PD endpoints), providing a full 80 mg/mL dose in a simple, patient-friendly format administered in < 10 seconds.

Articles

Key regulatory and pipeline updates span hematology, allergy, metabolic disease, rare endocrinology, and cardiorenal care. Agios halted tebapivat after phase 2 sickle cell data showed hematologic activity yet inadequate differentiation. FDA expanded Ryaltris intranasal olopatadine/mometasone to ages 6–11, extending the ≥12-year indication. Arrowhead reported SHASTA-3/4 phase 3 success for plozasiran in severe hypertriglyceridemia, including reduced acute pancreatitis. FDA accepted BridgeBio’s encaleret NDA for ADH1 with a May 2027 PDUFA. MannKind gained approval for Furoscix ReadyFlow with IV-equivalent exposure profiles.

Stay updated with the latest healthcare breakthroughs, including phase 3 plozasiran data in hypertriglyceridemia, the FDA approval of Furoscix ReadyFlow, and more.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Hematology

The HCPFive: Top News for Healthcare Providers from the Week of 07/19

Alex Hajduczok, MD, is an advanced heart failure and pulmonary hypertension specialist at Oklahoma Heart Institute. 

Philip Adamson, MD, MSc, is the chief medical officer of CVRx.

Can We Stop Heart Failure at Its Source?

In this segment from the latest episode of 

, host Alex Hajduczok, MD, a cardiologist and heart failure specialist at Oklahoma Heart Institute, sits down with Philip Adamson, MD, MSc, chief medical officer at CVRx, to discuss Adamson’s perspective on the recent advancements in heart failure care and the ongoing trials of future treatment techniques.

Check out the full episode on Adamson’s full cardiology career

The conversation begins with a reflection on the evolution of Adamson’s career and the continuity of his scientific focus despite transitioning across different areas of cardiovascular medicine. He explains that, although others have viewed these shifts as changes in specialty, his underlying objective has remained constant: understanding the fundamental mechanisms of disease. Emphasizing the importance of viewing medicine through the lens of pathophysiology rather than rigid sub-specialization, he argues that cardiovascular disorders cannot be fully understood in isolation. Instead, clinicians should recognize the complex interplay between the electrical, mechanical, autonomic, and circulatory systems that collectively influence cardiac function and disease progression.

The discussion then turns to the historical evolution of heart failure management, highlighting the shift from a hemodynamic model of disease to the now well-established neurohormonal hypothesis. Recalling the early 1990s, Adamson describes how the recognition that maladaptive neurohormonal activation drives heart failure progression fundamentally transformed therapeutic strategies. He reflects on the initial skepticism surrounding beta-blocker therapy, noting that many clinicians doubted the failing heart could improve structurally. Subsequent clinical evidence demonstrating reverse ventricular remodeling and improved survival, however, validated the concept that interventions targeting disease mechanisms could modify the natural history of heart failure rather than simply relieve symptoms.

Building on this framework, Adamson explains the physiologic role of the carotid baroreceptors as the body's primary sensors of circulatory status. He describes how reduced cardiac performance leads to diminished baroreceptor signaling, causing the brain to misinterpret heart failure as a state of hypovolemia or hemorrhage. This perceived threat initiates a cascade of maladaptive responses, including sympathetic nervous system activation, renin-angiotensin-aldosterone system stimulation, and inflammatory signaling. While current guideline-directed medical therapies effectively block many of these downstream pathways, he characterizes them as protecting target organs from the consequences of persistent neurohormonal activation rather than addressing its central origin.

The conversation subsequently focuses on baroreceptor activation therapy (BAT) as a novel strategy designed to intervene earlier in this pathophysiologic cascade. By electrically stimulating the carotid sinus nerve, BAT restores afferent signaling to central autonomic control centers, reducing sympathetic outflow, enhancing parasympathetic activity, and attenuating inflammatory responses. Adamson contrasts this approach with conventional pharmacologic therapies, describing it as an opportunity to reduce the neurohormonal "storm" itself rather than simply shielding organs from its downstream effects. He suggests that directly modulating the autonomic nervous system may provide a more comprehensive strategy for slowing heart failure progression.

To conclude the discussion, attention shifts to the ongoing Benefit HF trial, which Adamson notes is expected to enroll approximately 2,500 randomized patients, making it the largest device-based heart failure trial conducted to date. He explains that the study aligns with emerging perspectives reflected in recent heart failure consensus statements, which emphasize defining heart failure according to impaired cardiac function and underlying pathophysiology rather than relying solely on ejection fraction thresholds. By evaluating BAT in patients with ejection fractions below 50%, the trial seeks to determine whether earlier autonomic modulation can improve clinical outcomes across a broader population of patients with heart failure and further redefine the role of device-based therapies within contemporary heart failure management.

Editors’ Note: Hajduczok reports disclosures with CVRx, Edwards Lifesciences, and Impulse Dynamics. Adamson reports employment with CVRx.

The latest episode of Moving the Needle in Medicine features Philip Adamson, MD, MSc, as he discusses upcoming advancements in heart failure care.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Lessons From a Career Dedicated to Transforming Heart Failure Care

, host Alex Hajduczok, MD, a cardiologist and heart failure specialist at Oklahoma Heart Institute, sits down with Philip Adamson, MD, MSc, chief medical officer at CVRx, to discuss Adamson’s path through cardiology and his work with CVRx in heart failure.

Hajduczok and Adamson discuss the transformative potential of baroreflex activation therapy in heart failure, highlighting a patient case from the Oklahoma Heart Institute that demonstrated substantial physiologic improvements following Barostim therapy. They describe marked gains in exercise capacity, with the patient nearly doubling maximal workload during invasive cardiopulmonary exercise testing, alongside a significant reduction in pulmonary capillary wedge pressure. The case is presented as a powerful illustration of the broad physiologic effects of neuromodulation, reinforcing the concept that heart failure is a complex, systemic disease requiring interventions capable of influencing multiple interconnected pathways. Rather than targeting a single aspect of cardiac function, baroreflex activation therapy is described as modifying pulmonary vascular responses, left atrial and ventricular physiology, heart rate regulation, and exercise tolerance simultaneously. The speakers emphasize that understanding these effects requires a strong foundation in cardiovascular pathophysiology and express enthusiasm about completing and publishing the case report to share these findings with the broader heart failure community.

The conversation then shifts from clinical science to professional development, as Adamson reflects on a career spanning academic medicine, clinical research, industry, and innovation. Although his work has evolved over several decades and across different settings, he explains that the central purpose of his career has remained unchanged: finding better ways to improve the lives of patients with heart failure. Adamson notes that each transition provided new opportunities to expand his perspective while remaining focused on advancing patient care. In particular, his experience in industry exposed him to areas beyond traditional clinical practice, including international regulatory processes, reimbursement strategies, medical device development, and the challenges of bringing new technologies from clinical investigation into widespread clinical adoption. He describes these experiences as invaluable, providing a broader understanding of the many factors required to successfully translate innovation into meaningful clinical impact.

The speakers also explore the value of curiosity, resilience, and lifelong learning in both medicine and research. Reflecting on his career, Adamson stresses that failures and missteps should not be viewed as permanent setbacks but rather as opportunities to refine one's thinking and improve future decision-making. He emphasizes the importance of remaining intellectually flexible, acknowledging that long-held hypotheses may ultimately prove incorrect and that unexpected opportunities often emerge for those willing to recognize them. Drawing on the analogy of noticing "red cars" only after intentionally looking for them, he encourages clinicians and investigators to remain attentive to new possibilities rather than becoming constrained by preconceived expectations.

Throughout the discussion, Adamson conveys a deep sense of gratitude for witnessing the remarkable evolution of heart failure care over the past four decades. He recalls entering the field at a time when heart failure was widely regarded as a rapidly progressive and uniformly fatal condition with limited therapeutic options. In contrast, contemporary advances have dramatically improved survival, functional status, and quality of life, with some patients now achieving meaningful recovery. He concludes that these advances have reinforced the purpose that has guided his career from the beginning: continually seeking new ways to help patients live longer, healthier, and more fulfilling lives despite the challenges of heart failure.

The latest episode of Moving the Needle in Medicine features Philip Adamson, MD, MSc, as he walks through his long and successful career in cardiology.

show oral sebetralstat produced rapid, consistent symptom relief for breakthrough 

attacks in patients already on long-term prophylaxis (LTP) and left just 1.6% of attacks untreated.¹ Effectiveness was consistent regardless of which prophylactic agent patients were taking, with a median time to symptom relief of 1.3 hours.

Sebetralstat Resolves Breakthrough HAE Attacks Despite Prior Prophylaxis

The analysis evaluated 35 participants with HAE due to C1-inhibitor deficiency receiving LTP with berotralstat (n = 16), lanadelumab (n = 13), or C1 inhibitor replacement (n = 6).¹ Despite background prophylaxis, these participants experienced 504 breakthrough attacks and treated 382 of them (75.8%) with sebetralstat 600 mg, an oral plasma kallikrein inhibitor.¹

“Even people who are on those preventative therapies…can have breakthrough attacks of hereditary angioedema, and when that happens, the sebetralstat product worked well for them, even though it has an overlapping mechanism of action with some of those products," Investigator Daniel F. Soteres, MD, a physician from Asthma & Allergy Associates, PC, told 

He added that global guidelines call for every patient with HAE to keep 2 doses of on-demand medication available at all times in case an attack does not respond to the first.

KONFIDENT-S Data Show Consistent Relief Across LTP Regimens

Median time to beginning of symptom relief was 1.3 hours for participants on berotralstat, 1.3 hours for lanadelumab, and 1.8 hours for C1 inhibitor LTP.¹ Median time from attack recognition to sebetralstat administration was 6 minutes overall, ranging from 1 minute in participants on C1 inhibitor LTP to 20 minutes in those on berotralstat, and nearly 30% of attacks were treated while still mild.¹

Only 1.6% of the 504 breakthrough attacks went untreated, compared with roughly 50% of attacks in a prior real-world study of injectable on-demand therapy.¹ A second dose of sebetralstat was needed within 12 hours in 22.3% of attacks, and conventional injectable therapy was used in just 5.2% of sebetralstat-treated attacks.¹ Treatment-emergent adverse events occurred in 65.7% of participants, with 14.3% considered treatment-related, most commonly headache, nausea, and vomiting; no serious or severe treatment-related events were reported.¹

Counseling Patients Through Overlapping Mechanisms And Treatment Timing

Soteres said the overlapping mechanism of action between sebetralstat and kallikrein-inhibiting LTP agents was never a concern for him clinically.

"I'm an allergy and asthma doctor,” Soteres said. “We use overlapping mechanisms of action to treat disease in many regards.”

He also pointed to the oral, self-administered format as a likely driver of earlier treatment, since patients no longer need a private setting to self-inject and may feel more comfortable taking it. On setting expectations, Soteres cautioned that sebetralstat should not be framed to patients like an epinephrine autoinjector.

"It's not going to work in seconds," he said. “You do have to take the medicine and calm yourself. Let your loved one know what's going on and let the medicine do its job. You have to let the medicine do its work [for] over 20 minutes.”

Kinaciyan T, Aygören-Pürsün E, Martinez-Saguer I, et al. Sebetralstat for breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis in KONFIDENT-S. 

. 2026;5(5):100750. Published 2026 Jun 12. 

Johnson V. Sebetralstat Shows Long Term Fast Relief of Breakthrough HAE Attacks. HCPLive. Published July 21, 2026. Accessed July 24, 2026. 

New international guideline for HAE management - HAE International (HAEi). HAE International (HAEi). Published May 3, 2022. Accessed July 24, 2026. 

https://haei.org/new-international-guideline-for-hae-management/

Interim KONFIDENT-S results indicate oral sebetralstat 600 mg enabled rapid, consistent control of breakthrough hereditary angioedema attacks among patients with C1-inhibitor deficiency receiving long-term prophylaxis (berotralstat, lanadelumab, or C1 inhibitor). Across 504 attacks, median time to initial symptom relief was ~1.3 hours (1.8 hours with C1 inhibitor prophylaxis), and only 1.6% of attacks were untreated. Early, self-administered dosing likely supported prompt use, with acceptable tolerability and no serious treatment-related events.

Daniel Soteres, MD, discusses KONFIDENT-S data showing sebetralstat quickly resolves breakthrough HAE attacks in patients on long-term prophylaxis

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for 

. He is also the executive producer of two podcasts: 

. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Sanofi has discontinued development of OX40L-targeting amlitelimab for atopic dermatitis, following the heels of Kyowa Kirin's similar rocatinlimab discontinuation.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Sanofi Announces Discontinuation of Amlitelimab for Atopic Dermatitis

Mandana Khalili, MD, is Chief of Clinical Hepatology and Director of Clinical and Translational Research in Hepatology at San Francisco General Hospital, and directs the UCSF T32 Hepatology Training Program.

Telehealth stepped alcohol treatment reduced weekly drinking, but not the primary endpoint, among patients with chronic liver disease.

Hepatology

MASH / MASLD

The HCPLive MASH & MASLD page is a comprehensive resource for clinical news and insights on metabolic dysfunction-associated steatotic liver disease and steatohepatitis. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for fatty liver disease, steatohepatitis, and more.

Telehealth Stepped Alcohol Care Reduced Drinking in Liver Disease

Jason Hawkes, MD, explains how new biologics and targeted therapies are advancing precision medicine and improving personalized care in atopic dermatitis.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Q&A: How Is Precision Medicine Changing Atopic Dermatitis Care? With Jason Hawkes, MD

Abigail Brooks is a strategic content lead overseeing 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

The approval makes MannKind Corporation’s furosemide injection the first and only autoinjector delivering SC furosemide with IV-equivalent exposure.

Chronic Kidney Disease

FDA News

David Golden, MD, clinical associate professor of medicine at Johns Hopkins University School of Medicine.

David B.K. Golden, MD, of Johns Hopkins, discusses anaphylaxis counseling, the Anaphylm CRL, and why a new epinephrine guideline is still years away.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Shared Decision-Making Guides Epinephrine Delivery Choice

GLP-1 receptor agonists show early promise for psoriasis and HS, but 3 experts urge caution on mechanism, durability, and long-term safety.

GLP-1s in Dermatology: Emerging Evidence and Unanswered Questions

Ron Blankstein, MD, is the associate director of the cardiovascular imaging program, director of cardiac computed tomography, and co-director of the cardiovascular imaging training program at Brigham and Women’s Hospital, as well as a professor of medicine at Harvard Medical School.

Ron Blankstein, MD, explains the value of PCD-CT and its consistency in both data collection and analysis of plaque with prior technology.

Atherosclerotic Cardiovascular Disease

Photon-Counting CT Plaque Analysis Consistent With Energy-Integrating Detector CT

IgA nephropathy shows a male predominance, but researchers have not identified why. Ramy Hanna, MD explores possible biological explanations.


IgA Nephropathy

The HCPLive Berger disease page is a resource for medical news and expert insights on IgA nephropathy. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in Berger disease, and more.

Why Does IgA Nephropathy Affect More Men? With Ramy Hanna, MD 

Chelsie Derman is an associate editor for 

who covers allergy and  psychiatry. She joined MJH Life Sciences in September 2023 after graduating from The College of New Jersey with a bachelor’s degree in journalism and professional writing. In her free time, she enjoys creative writing and reading.

Allergists explain what's settled about epinephrine nasal spray, what's not, and how to counsel patients before anaphylaxis guidelines catch up.

Epinephrine Nasal Spray Is Here. Updated Anaphylaxis Guidelines Aren't.

Victoria Johnson joined MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and is now an assistant managing editor for HCPLive and RheumatologyLive. She doesn’t have enough time for her numerous hobbies. You can reach her at vjohnson@mjhlifesciences.com.

APPs discuss insurance barriers, dupilumab as the default COPD biologic, depemokimab adherence advantages, and why pulmonary rehab remains critically underused.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Latest News

Sebetralstat Shows QoL Gains on Top of HAE Prophylaxis in KONFIDENT-S

The HCPFive: Top News for Healthcare Providers from the Week of 07/19

Can We Stop Heart Failure at Its Source?

Lessons From a Career Dedicated to Transforming Heart Failure Care

Sebetralstat Resolves Breakthrough HAE Attacks Despite Prior Prophylaxis